Home > Boards > US Listed > Biotechs > Affimed Therapeutics (AFMD)

I compared $FATE to $AFMD. $FATE currently trades

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
BobDoleYahoo Member Profile
 
Followed By 52
Posts 788
Boards Moderated 0
Alias Born 07/11/17
160x600 placeholder
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/10/2020 8:12:48 AM
Affimed Announces Annual General Meeting of Shareholders GlobeNewswire Inc. - 7/10/2020 6:30:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/23/2020 6:45:15 AM
Affimed Reports First Quarter 2020 Financial Results and Operational Progress GlobeNewswire Inc. - 6/23/2020 6:30:00 AM
Affimed Announces Presentation of Data on Genentech’s RO7297089 and AFM24, Both Innate Cell Engagers Developed from Affimed... GlobeNewswire Inc. - 6/22/2020 9:20:00 AM
Affimed Announces Successful Completion of First Dose Cohort in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of... GlobeNewswire Inc. - 6/17/2020 6:30:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 6/16/2020 10:56:13 AM
Affimed to Report First Quarter 2020 Financial Results & Corporate Update June 23, 2020; Company to Participate in Virtual BM... GlobeNewswire Inc. - 6/16/2020 6:30:00 AM
Affimed Announces Appointment of Angus Smith as Chief Financial Officer GlobeNewswire Inc. - 6/11/2020 6:30:00 AM
Affimed Highlights Study Design of its AFM13 REDIRECT Trial at the ASCO 2020 Virtual Meeting GlobeNewswire Inc. - 5/29/2020 8:05:00 AM
Affimed to Present at the Jefferies Virtual Healthcare Conference GlobeNewswire Inc. - 5/28/2020 5:00:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 5/26/2020 4:30:57 PM
Affimed Announces Abstracts on Innate Cell Engagers from its ROCK® Platform Accepted for Presentation at AACR Virtual Annual... GlobeNewswire Inc. - 5/15/2020 5:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/13/2020 4:33:10 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/13/2020 4:32:30 PM
Schedule 13g Edgar (US Regulatory) - 5/8/2020 8:10:57 AM
Annual and Transition Report (foreign Private Issuer) (20-f) Edgar (US Regulatory) - 4/28/2020 5:04:54 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 4/28/2020 6:49:07 AM
Affimed Reports 2019 Financial Results and Recent Operational Progress GlobeNewswire Inc. - 4/28/2020 6:35:00 AM
Affimed Announces First Patient Successfully Dosed in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of Advanced ... GlobeNewswire Inc. - 4/16/2020 7:30:00 AM
Affimed Provides COVID-19-Related Business Update and Announces Full Year 2019 Financial Results Conference Call on April 28,... GlobeNewswire Inc. - 4/2/2020 6:30:00 AM
Affimed Announces FDA Granted Orphan Drug Designation for Lead Innate Cell Engager AFM13 for the Treatment of T-cell Lymphoma... GlobeNewswire Inc. - 4/1/2020 4:01:00 PM
Affimed Announces Participation at Upcoming Virtual Investor Conferences GlobeNewswire Inc. - 3/26/2020 7:30:00 AM
Affimed Announces Appointment of Arndt Schottelius, M.D. Ph.D. as Chief Scientific Officer GlobeNewswire Inc. - 3/17/2020 7:30:00 AM
Affimed to Present at the SVB Leerink 9th Annual Global Healthcare Conference GlobeNewswire Inc. - 2/19/2020 7:30:00 AM
BobDoleYahoo   Thursday, 08/30/18 04:35:00 AM
Re: None
Post # of 206 
I compared $FATE to $AFMD. $FATE currently trades at double value w/ similar pipeline. $AFMD should be trading double $ digits. This is by far the best read. Even Zack's is wrong on the closing date. They quoted 3rd quarter 2019. It's 2018. I wrote them to let them know they made a typo. So as I and others have already noted, the $96 million + $5 billion is just part of it. Affirmed will also get additional $$ from net sales royalties.

The ABSOLUTE best part is: Genentech is willing to foot most of the R&D expense. That means less dilution & more money reimbursed. Plus since they are projected to last through 2019 with their current cash BEFORE the deal, the CEO expects the $24 million per month (which is close to what they burn per year) to extend that out much further. My guess is possibly another full year, possibly two into 2020-2021, even with ramped up R&D.

http://www.bioworld.com/content/96m-committed-affimed-shares-surge-150-potential-51b-genentech-deal-0

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist